Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Investor Presentation (November 2015)
20 slides from Ani Pharmaceuticals's investor presentation, Nov 10, 2015
Slide 1: Corporate Presentation November 2015
A Specialty Pharmaceutical Company NASDAQ: ANIP GENERIC AND BRANDED PRESCRIPTION DRUG PRODUCTS Corporate Presentation November 2015
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements To the extent any statements made in this presentation deal with information that is not historical, these are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, stat
Slide 3: ANI Mission Statement
3 3 ANI Mission Statement ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, anti - cancer (oncolyti
Slide 4: ANI Overview – Positioned for Growth
4 ANI Overview – Positioned for Growth ANI Today ▪ Current business – For the quarter ended September 30, 2015: $20.0 million total net revenues □ $15.1 million Generic Rx product revenues +48% y/y □ $2.3 million Brand Rx product revenues - 53% y/y □ $2.6 million c ontract manufacturing/services rev
Slide 5: ANI History and Highlights
5 5 ANI History and Highlights 2013 Completed merger with BioSante Pharmaceuticals and obtains NASDAQ Global Market listing (NASDAQ: ANIP), June 2013 2013 Announced agreement to acquire 31 previously marketed generic products from Teva for $12.5 million and a percentage of future gross profits, Dece
Slide 6: Sales and Marketing Overview
6 6 Sales and Marketing Overview
Slide 7: ANI Historical Revenue Growth
7 ANI Historical Revenue Growth 7 $s in millions 39% C ost of sales as a percentage of net revenues, excluding depreciation and amortization 42% 43% 33% 21% 16%
Slide 8: ANI Generic Rx Product Portfolio
8 ANI Generic Rx Product Portfolio Generic Products Market Share (1) Competitors (2) EE/MT Tablets 49% 3 Fluvoxamine Tablets 55% 3 HC Enema 80% 2 Metoclopramide Solution 22% 2 Opium Tincture 74% 3 Methazolamide Tablets 40% 3 Etodolac Capsules 19% 3 Propafenone Tablets 3% 4 Oxycodone Solution Launche
Slide 9: ANI Brand Rx Product Portfolio
9 ANI Brand Rx Product Portfolio 9 Lithobid ® Tablets Bipolar Disorder Vancocin ® Capsules C. difficile - Associated Diarrhea Cortenema ® U lcerative Colitis Reglan ® Gastroesophageal Reflux 3Q 2015 Net Sales: $2.3M
Slide 10: ANI Contract Manufacturing and Other Current Business
10 ANI Contract Manufacturing and Other 10 Current Business ▪ Four customers – Seven products and seventeen SKUs – Contract manufacturing and contract packaging 3Q 2015 Net Sales: $2.6M
Slide 11: Business Development / Product Development Overview
11 11 Business Development / Product Development Overview
Slide 12: Business Development Activity
12 Business Development Activity 12 $1.1 $0.1 G e n e r i c s GENERIC PRODUCT (Partnership with Dexcel) FDF Partnership Private P TEVA ANDA BASKET 2 (22 previously approved ANDAs) TEVA ANDA BASKET 1 (31 previously approved ANDAs) Total $142.2 FDF Partnership Private Acquisition Public P P P $25.0 P
Slide 13: ANI Product Development Pipeline
13 13 ANI Product Development Pipeline 85 p roducts in development, total combined current market: $4.6 billion (1) ▪ 54 products were acquired and of those, ANI believes 47 can be commercialized based on either a CBE - 30 or PAS ▪ ANI anticipates launching ten products by the end of 2016: (1) Based
Slide 14: Manufacturing Overview
14 14 Manufacturing Overview
Slide 15: ANI Manufacturing – Main Street Facility
15 15 ANI Manufacturing – Main Street Facility Location: Baudette , Minnesota ▪ 52,000 square feet of manufacturing , packaging, and warehouse facilities ▪ Rx solutions , suspensions , topicals , tablets , and capsules ▪ DEA - licensed for Schedule II controlled substances ▪ 17,000 square feet of la
Slide 16: ANI Manufacturing – IDC Road Facility
16 16 ANI Manufacturing – IDC Road Facility Location: Baudette, Minnesota ▪ Fully - contained h igh potency facility with capabilities to manufacture h ormone , steroid , and oncolytic products ▪ 47,000 square feet of manufacturing and packaging, and warehouse facilities ▪ 100 nano - gram per eight
Slide 17: ANI Summary
17 ANI Summary ANI is an integrated specialty generic pharmaceutical firm with: ▪ Profitable base business generating organic growth – 2015 Annual guidance (1) □ Net revenues of $75.5 million to $78.3 million □ Adjusted non - GAAP EBITDA of $43.3 million to $45.4 million □ Adjusted non - GAAP Net In
Slide 18: Appendix A
18 18 Appendix A
Slide 19: U.S. GAAP Reconciliations
19 U.S. GAAP Reconciliations 19 2015 2014 2015 2014 Operating Income $8,451 $8,199 $26,432 $9,234 Add back Depreciation and amortization 2,047 1,187 4,789 2,596 Add back Stock-based compensation 1,120 692 2,717 2,719 Adjusted non-GAAP EBITDA $11,618 $10,078 $33,938 $14,549 ANI Pharmaceuticals, Inc.
Slide 20: U.S. GAAP Reconciliations
20 U.S. GAAP Reconciliations 20 Three months ended September 30, 2015 Nine months ended September 30, 2015 Net Income 4,559$ $ 12,499 Add back Tax provision 1,098 5,733 Depreciation and amortization expense 2,047 4,789 Non-cash interest expense 1,721 5,109 Stock-based compensation 1,120 2,717 Less C
ANI Pharmaceuticals — Investor Presentation (November 2015) on 6ix